TY - JOUR
T1 - Association of Low-Attenuation Plaque with Impaired Glucose Tolerance and Type 2 Diabetes Mellitus in Patients with Suspected Coronary Artery Disease
AU - Rueskov Andersen, Thomas
AU - Overgaard, Katrine S
AU - Heinsen, Laurits Juhl
AU - Mohamed, Roda Abdulkadir
AU - Precht, Helle
AU - Lambrechtsen, Jess
AU - Auscher, Søren
AU - Egstrup, Kenneth
PY - 2025/1
Y1 - 2025/1
N2 - AIM: The aim of this study was to evaluate the differences in plaque composition and burden between normal glycemic status (NGS) and dysglycemia expressed as impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM).METHODS: Clinically indicated coronary computed tomography angiography was used to evaluate patients with suspected coronary artery disease (CAD). An oral glucose tolerance test was performed to assess glycemic status. Patients were stratified as NGS, IGT, and T2DM. Plaque volumes were quantified using validated software, with further compositional measurements of low-attenuation, non-calcified, and calcified plaque burden.RESULTS: Of 355 patients with suspected CAD, 220 had NGS, 92 were diagnosed with IGT, and 43 with known T2DM. Low-attenuation plaque volume was significantly higher in IGT (209 mm
3,
p < 0.02) and T2DM (243 mm
3,
p = 0.005) compared with NGS (166 mm
3). Total plaque burden was similar between all groups, but a significantly greater low-attenuation plaque burden was seen in IGT (
p = 0.03) and T2DM (
p = 0.02) compared with NGS. The multivariate linear regression model adjusted for clinical risk factors showed that patients with IGT had a greater low-attenuation plaque burden compared with those with NGS (
p = 0.03). Interestingly, no significant differences in plaque burdens were observed between those with IGT and T2DM in both univariate and multivariate analyses.
CONCLUSIONS: Dysglycemia, including impaired glucose tolerance and type 2 diabetes mellitus, was associated with increased low-attenuation plaque burden compared with normal glycemic status. Patients with IGT demonstrated plaque burden similar to patients with known T2DM, underscoring the need for early metabolic intervention.
AB - AIM: The aim of this study was to evaluate the differences in plaque composition and burden between normal glycemic status (NGS) and dysglycemia expressed as impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM).METHODS: Clinically indicated coronary computed tomography angiography was used to evaluate patients with suspected coronary artery disease (CAD). An oral glucose tolerance test was performed to assess glycemic status. Patients were stratified as NGS, IGT, and T2DM. Plaque volumes were quantified using validated software, with further compositional measurements of low-attenuation, non-calcified, and calcified plaque burden.RESULTS: Of 355 patients with suspected CAD, 220 had NGS, 92 were diagnosed with IGT, and 43 with known T2DM. Low-attenuation plaque volume was significantly higher in IGT (209 mm
3,
p < 0.02) and T2DM (243 mm
3,
p = 0.005) compared with NGS (166 mm
3). Total plaque burden was similar between all groups, but a significantly greater low-attenuation plaque burden was seen in IGT (
p = 0.03) and T2DM (
p = 0.02) compared with NGS. The multivariate linear regression model adjusted for clinical risk factors showed that patients with IGT had a greater low-attenuation plaque burden compared with those with NGS (
p = 0.03). Interestingly, no significant differences in plaque burdens were observed between those with IGT and T2DM in both univariate and multivariate analyses.
CONCLUSIONS: Dysglycemia, including impaired glucose tolerance and type 2 diabetes mellitus, was associated with increased low-attenuation plaque burden compared with normal glycemic status. Patients with IGT demonstrated plaque burden similar to patients with known T2DM, underscoring the need for early metabolic intervention.
KW - computed coronary tomography angiography
KW - dysglycemia
KW - impaired glucose tolerance
KW - low-attenuation plaque
KW - plaque burden
KW - plaque composition
KW - type 2 diabetes mellitus
U2 - 10.3390/biomedicines13010028
DO - 10.3390/biomedicines13010028
M3 - Journal article
C2 - 39857612
SN - 2227-9059
VL - 13
JO - Biomedicines
JF - Biomedicines
IS - 1
M1 - 28
ER -